Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report
Tóm tắt
We present a 35-year-old female patient who was started on rifampicin (900 mg orally once daily) and trimethoprim/sulfamethoxazole (TMP/SMX) (160/800 mg orally twice daily) after being diagnosed with brucellosis. Following defervescence and improvement in her general condition, fever recurred on the 12th day of treatment. A re-challenge drug test lead to causality assessment and treatment was switched to a combination of streptomycin (1 g intramuscularly) for 10 days and TMP/SMX (160/800 mg orally twice daily) for 4 weeks. Our patient is doing well after 12 months of follow-up.
Tài liệu tham khảo
Vodovar D, Le Beller C, Mégarbane B, Lillo-Le Louet A. Drug fever. Adverse Drug React Bull. 2014;284(1):1095–8. https://doi.org/10.1097/fad.0000000000000002.
Patel RA, Gallagher JC. Drug fever. Pharmacotherapy. 2010;30(1):57–69. https://doi.org/10.1592/phco.30.1.57.
Tabor PA. Drug-induced fever. Drug Intell Clin Pharm. 1986;20(6):413–20.
Roush MK, Nelson KM. Understanding drug-induced febrile reactions. Am Pharm. 1993;33(10):39–42.
Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med. 1987;106(5):728–33.
Oizumi K, Onuma K, Watanabe A, Motomiya M. Clinical study of drug fever induced by parenteral administration of antibiotics. Tohoku J Exp Med. 1989;159(1):45–56.
Meena LP, Rai M, Pathak A, Garg S, Bharti A. Rifampicin-Induced Fever. IOSR J Pharm Biol Sci. 2012;2(1):25–6.
Wilson SM. Temperature Dysregulation. In: Tisdale JE, Miller DA, editors. Drug-induced diseases: prevention, detection, and management: American Society of Health System Pharmacists; 2010. p. 644–85.
Cluff LE, Johnson JE. Drug fever. In: Kallós P, Waksman B, editors. Progress in Allergy Vol 8 Chem Immunol Allergy. 8. Basel: Karger Publishers; 1964. p. 149–94.
Das SK, Jana PK, Bairagya TD, Das A. Isoniazid and rifampicin induced fever in a patient with tuberculous pleural effusion. Saudi J Health Sci. 2014;3(1):47–9. https://doi.org/10.4103/0971-9903.202018.
Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore). 1999;78(6):361–9.
Sadanshiv M, George AA, Mishra AK, Kuriakose CK. Rifampicin-induced immune allergic reaction. Trop Doct. https://doi.org/10.1177/0049475517724689.
Havey TC, Cserti-Gazdewich C, Sholzberg M, Keystone JS, Gold WL. Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. Am J Trop Med Hyg. 2012;86(2):264–7. https://doi.org/10.4269/ajtmh.2012.11-0598.
Ip M, Cheng KP, Cheung WC. Disseminated intravascular coagulopathy associated with rifampicin. Tubercle. 1991;72(4):291–3.
Nowicka J, Kotschy M, Chwistecki K, Jelen M. Disseminated intravascular coagulation (DIC) during superacute haemolysis in a patient with ovarian dermatoid cyst treated with rifampicin. Haematologia (Budap). 1977;11(3–4):359–64.
Souza CS, Alberto FL, Foss NT. Disseminated intravascular coagulopathy as an adverse reaction to intermittent rifampin schedule in the treatment of leprosy. Int J Lepr Other Mycobact Dis. 1997;65(3):366–71.
Lipsky BA, Hirschmann JV. Drug fever. JAMA. 1981;245(8):851–4.
Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–50.
Bedi RS. Rifampicin induced fever : a case report. Indian J Tuberc. 1991;38(4):233–4.
Matz J, Borish LC, Routes JM, Rosenwasser LJ. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med. 1994;149(3 Pt 1):815–7. https://doi.org/10.1164/ajrccm.149.3.8118654.
Kobashi Y, Abe T, Shigeto E, Yano S, Kuraoka T, Oka M. Desensitization therapy for allergic reactions to antituberculous drugs. Intern Med. 2010;49(21):2297–301.
Cook SV, Fujiwara PI, Frieden TR. Rates and risk factors for discontinuation of rifampicin. Int J Tuberc Lung Dis. 2000;4(2):118–22.
Holland CL, Malasky C, Ogunkoya A, Bielory L. Rapid oral desensitization to isoniazid and rifampin. Chest. 1990;98(6):1518–9.
Sanchez-Borges M, Thong B, Blanca M, Ensina LF, Gonzalez-Diaz S, Greenberger PA, et al. Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organ J. 2013;6(1):18. https://doi.org/10.1186/1939-4551-6-18.
Vodovar D, LeBeller C, Megarbane B, Lillo-Le-Louet A, Hanslik T. Drug fever: a descriptive cohort study from the French national pharmacovigilance database. Drug Saf. 2012;35(9):759–67. https://doi.org/10.2165/11630640-000000000-00000.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.